 JENA, Germany, March 01, 2021 GLOBE NEWSWIRE -- InflaRx N.V. Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of 15,000,000 common shares at a price of 5.00 per share. For each common share purchased, an investor received a warrant to purchase a common share at an exercise price of 5.80. The gross proceeds to InflaRx from the offering were approximately 75 million, before deducting the underwriting discount and other offering expenses and excluding the exercise of any warrants. The Company intends to use the net proceeds from the offering primarily to fund research and development expenses for its clinical and preclinical research and development activities and for working capital and general corporate purposes. 